Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams bought 18,529 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average cost of $1.02 per share, for a total transaction of $18,899.58. Following the completion of the transaction, the director now owns 13,822,919 shares in the company, valued at $14,099,377.38. This trade represents a 0.13 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Gregg Williams also recently made the following trade(s):
- On Friday, April 11th, Gregg Williams purchased 2,311 shares of Vivani Medical stock. The shares were purchased at an average cost of $1.01 per share, with a total value of $2,334.11.
- On Monday, April 7th, Gregg Williams acquired 44,400 shares of Vivani Medical stock. The stock was purchased at an average cost of $0.99 per share, for a total transaction of $43,956.00.
- On Friday, April 4th, Gregg Williams bought 34,000 shares of Vivani Medical stock. The shares were purchased at an average cost of $0.99 per share, with a total value of $33,660.00.
- On Wednesday, April 2nd, Gregg Williams purchased 2,000 shares of Vivani Medical stock. The stock was acquired at an average price of $1.01 per share, for a total transaction of $2,020.00.
Vivani Medical Stock Performance
Shares of VANI opened at $1.02 on Friday. The business's 50-day moving average is $1.09 and its two-hundred day moving average is $1.19. The company has a market capitalization of $60.42 million, a P/E ratio of -2.27 and a beta of 2.76. Vivani Medical, Inc. has a fifty-two week low of $0.91 and a fifty-two week high of $2.09.
Vivani Medical (NASDAQ:VANI - Get Free Report) last posted its earnings results on Monday, March 31st. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Analysts forecast that Vivani Medical, Inc. will post -0.41 EPS for the current year.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a "buy" rating and issued a $4.00 price objective on shares of Vivani Medical in a report on Friday, April 4th.
View Our Latest Research Report on Vivani Medical
Institutional Investors Weigh In On Vivani Medical
Hedge funds and other institutional investors have recently made changes to their positions in the company. Northern Trust Corp grew its position in shares of Vivani Medical by 19.1% during the 4th quarter. Northern Trust Corp now owns 71,915 shares of the company's stock valued at $83,000 after acquiring an additional 11,540 shares during the period. Geode Capital Management LLC raised its holdings in Vivani Medical by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 342,891 shares of the company's stock worth $401,000 after purchasing an additional 15,008 shares during the period. Wealthedge Investment Advisors LLC purchased a new position in Vivani Medical during the fourth quarter worth approximately $43,000. Finally, Jane Street Group LLC acquired a new stake in Vivani Medical in the fourth quarter valued at approximately $66,000. Institutional investors and hedge funds own 6.78% of the company's stock.
About Vivani Medical
(
Get Free Report)
Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
